Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to MarketBusiness Wire • 06/29/22
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast CancerBusiness Wire • 06/27/22
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete ResectionBusiness Wire • 06/24/22
CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and ChildrenBusiness Wire • 06/22/22
U.S. FDA Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and ChildrenBusiness Wire • 06/22/22
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM EvidenceBusiness Wire • 06/21/22
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human HealthBusiness Wire • 06/21/22